TrialThe lancet. Gastroenterology & hepatology2025

Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2-F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study.

Vincent Wai-Sun Wong et al.PubMed ↗Publisher ↗

No numbers read from the abstract.